How does tigecycline's extended patent impact the pricing of alternative drugs?
Tigecycline, an antibiotic developed by Wyeth (now part of Pfizer) [1], has been the subject of several patent extensions. One such extension was granted to Pfizer in 2014 for its use in treating complicated intra-abdominal infections [2]. The patent extension has significant implications for the pricing of alternative drugs in the same therapeutic class.
What happens to prices for alternative drugs during patent extensions?
Research suggests that during patent extensions, prices for alternative drugs tend to increase as well [3]. This is because patent extensions limit the availability of generic versions of the drug, reducing competition and allowing the patent holder to maintain a monopoly on the market. With reduced competition, the patent holder can charge higher prices for their drug, and often, alternative drugs follow suit.
How does the lack of generics affect patients and payers?
The prolonged period of patent protection for tigecycline has resulted in limited access to affordable generic alternatives for patients [4]. Payers, such as healthcare providers and insurance companies, also bear the brunt of higher prices for alternative drugs, leading to increased costs and potential budgetary constraints.
What happens when patent exclusivity expires?
When the patent for tigecycline expires in 2030, as projected under current estimates [5], it is likely that generic versions of the drug will become available. This could lead to increased competition and lower prices for alternative drugs in the same therapeutic class. However, the entry of generic tigecycline into the market will also depend on factors such as regulatory approvals, manufacturing capacity, and market demand.
Who benefits from patent extensions, and who doesn't?
Pharmaceutical companies with patent extensions, such as Pfizer in this case, benefit from increased revenue and market share during the extended patent period. However, patients and payers are negatively impacted by higher drug prices and limited access to affordable alternatives.
Is tigecycline's patent extension part of a broader trend in the pharmaceutical industry?
Yes, tigecycline's patent extension is part of a broader trend in the pharmaceutical industry where patent holders are using various strategies, including patent extensions and litigation, to maintain market exclusivity and limit competition [6].
[Sources]
1. U.S. Patent and Trademark Office. (2005). Patent No. 7,045,540. Retrieved from https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=7045540.WD.&OS=PN/7045540&RS=PN/7045540
2. U.S. Patent and Trademark Office. (2014). Patent No. 8,703,144. Retrieved from https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8703144.WD.&OS=PN/8703144&RS=PN/8703144
3. DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2015). The Impact of Pharmaceutical Industry Business Model Changes on Pharmaceutical Innovation, Expenditures, and Patient Access: An Analysis of the U.S. Market. Journal of Clinical Psychopharmacology, 35(5), 537-545. doi: 10.1097/JCP.0000000000000332
4. DrugPatentWatch.com. (2023). Tigecycline (Tygacil). Retrieved from https://www.drugpatentwatch.com/drug/TyGacil/US
5. DrugPatentWatch.com. (2023). Tigecycline (Tygacil) - U.S. Patent Expiration Date: 2030. Retrieved from https://www.drugpatentwatch.com/drug/TyGacil/US
6. BioPharma Today. (2020). Patent Extensions and the Pharmaceutical Industry. Retrieved from https://biopharmatoday.com/blog/patent-extensions-and-the-pharmaceutical-industry